AnalystsEric SchmidtEric Schmidt's Stock Forecasts
AnalystsEric Schmidt
Sectors:
Industries:
Analyst Ranking
Top 29%
#1447 out of 5116 analysts
Average Return
+18.14%
Win Rate
47%7 out of 15
Risk vs Reward
Poor
Good
Eric Schmidt's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Avidity Biosciences IncRNA | +146.99% | $29.03 | $71.70 | 2025-06-27 - 2025-11-28 | Strong Buy |
G1 Therapeutics IncGTHX | +129.24% | $17.99 | $41.24 | 2017-06-12 - 2018-06-12 | Buy |
Bioverativ IncBIVV | +68.97% | $62.13 | $104.98 | 2017-07-10 - 2018-03-08 | Buy |
Bicara Therapeutics IncBCAX | +39.03% | $13.35 | $18.56 | 2025-03-13 - 2025-11-28 | Strong Buy |
Avidity Biosciences IncRNA | +34.04% | $23.97 | $32.13 | 2024-03-14 - 2025-03-13 | Strong Buy |
Eric Schmidt Analyst Color
Get additional color on Eric Schmidt's coverage of popular stocks
Eric Schmidt's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Legend Biotech CorpLEGN | 2 | Strong Buy | $75.00 | +170.66% | Maintains | 17 days ago |
Arcellx IncACLX | 1 | Hold | $88.00 | +21.03% | Assumes | 2 months ago |
Avidity Biosciences IncRNA | 5 | Strong Buy | $96.00 | +33.89% | Reiterates | 5 months ago |
Bicara Therapeutics IncBCAX | 1 | Strong Buy | $13.01 | -29.90% | Reiterates | 9 months ago |
Biogen IncBIIB | 3 | Strong Buy | $292.00 | N/A | Reiterates | a year ago |
Vertex Pharmaceuticals IncVRTX | 1 | Strong Buy | $370.00 | N/A | Reiterates | 2 years ago |
Bioverativ IncBIVV | 1 | Buy | N/A | N/A | Upgrades | 8 years ago |
G1 Therapeutics IncGTHX | 1 | Buy | $31.00 | N/A | Initiates Coverage On | 8 years ago |
Ovid Therapeutics IncOVID | 1 | Buy | N/A | N/A | Initiates Coverage On | 8 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.